Research programme: p53 upregulated modulator of apoptosis stimulants - Merck & Co
Alternative Names: ARQ-850RP; Research programme: PUMA stimulants - ArQuleLatest Information Update: 20 Jan 2020
At a glance
- Originator ArQule
- Developer Merck & Co
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 31 May 2006 This programme is still in active development
- 31 Aug 2005 Preclinical trials in Solid tumours in USA (unspecified route)